Why Ardelyx, Inc.’s (ARDX) Stock Is Down 6.04%
As of Monday, June 29, Ardelyx, Inc.’s ARDX share price has dipped by 6.04%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Commentary & Analysis
Why Ardelyx, Inc.’s (ARDX) Stock Is Down 5.37%
As of Wednesday, May 13, Ardelyx, Inc.’s ARDX share price has dipped by 5.37%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Ardelyx, Inc.’s (ARDX) Stock Is Up 5.01%
As of Monday, May 04, Ardelyx, Inc.’s ARDX share price has surged by 5.01%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Ardelyx, Inc.’s (ARDX) Stock Is Up 8.21%
As of Friday, May 01, Ardelyx, Inc.’s ARDX share price has surged by 8.21%, which has investors questioning if this is right time to sell.Rosalio Madrigal
What You Need to Know About Ardelyx, Inc.'s Q2 Earnings
Ardelyx, Inc.'s fiscal Q2 earnings report was released on Thursday, April 30. Let's dive in to see if (ARDX) missed or beat analyst's expectations.Rosalio Madrigal
Financial Summary
| Share Statistics | ARDX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,245.0 | $251.9 | 48% |
|
| Shares Out (Mil) | 245.9 | 50.8 | 80% |
|
| Institutional Ownership | 94.3% | 92.0% | 65% |
|
| Float (Mil) | 219.8 | 40.5 | 76% |
|
| Beta | 0.61 | 0.95 | 35% |
|
| Avg Daily Volume (000s) | 2,365 | 447 | 85% |
|
| Price Change (52-week) |
19.4% | 54.2% | 61% |
|
| Growth | ARDX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 121.7% | 14.0% | 99% |
|
| Net Income (5yr) | 8.2% | (9.8%) | 52% |
|
| EPS (5yr) | 24.6% | 16.3% | 74 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 15.0% | (15.6%) | 73% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($0.050) | ($0.052) | $0.515 | |
| Month Ago EPS | ($0.037) | ($0.048) | $0.515 | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.032) | ($0.003) | $0.513 | |
| Year/Year Chg | (67.3%) | (79.7%) | (529.7%) | |
| Financials | ARDX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $428 | $39 | 40% |
|
| Net Income (TTM) (Mil) | ($58) | ($43) | 15% |
|
| EPS (TTM) | ($0.239) | ($1.600) | 33% |
|
| Operating Cash Flow (TTM) (Mil) | ($36) | ($30) | 11% |
|
| Net Cash Flow (TTM) (Mil) | $0 | $3 | 45% |
|
| Long-Term Debt (Q1) (Mil) | $233 | $5 | 52% |
|
| Enterprise Value (Q1) (Mil) | $1,488 | $182 | 46% |
|
| Valuation | ARDX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 8.40 | 2.60 | 88% |
|
| P/E | na | 18.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ARDX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 74.6% | 63.8% | 85% |
|
| Net Margin | (13.6%) | (64.7%) | 19% |
|
| ROA | (12.7%) | (49.7%) | 24% |
|
| ROE | (39.5%) | (55.4%) | 17% |
|
| Liabilities to Assets | 70.5% | 30.3% | 66% |
|
| F-Score | 3 | 3 | 19% |
|
Ardelyx, Inc. did not pass any screens on 7/30/2026.
